vs
Cytek Biosciences, Inc.（CTKB）与Prenetics Global Ltd（PRE）财务数据对比。点击上方公司名可切换其他公司
Cytek Biosciences, Inc.的季度营收约是Prenetics Global Ltd的14.5倍（$62.1M vs $4.3M）
Cytek Biosciences主营高性能流式细胞分析系统、配套试剂及分析软件的研发、生产与商业化，产品服务覆盖生命科学研究、临床诊断、生物制药开发等领域，客户遍及全球多个主要地区。
Prenetics是一家总部位于中国香港的健康科学企业，业务辐射美国地区，专注于癌症等疾病的早期筛查、预防与干预诊疗，致力于帮助人们更早发现健康风险，助力提升相关疾病的治疗效果，推动肿瘤等重疾的早防早治，守护公众健康。
CTKB vs PRE — 直观对比
营收规模更大
CTKB
是对方的14.5倍
$4.3M
损益表 — Q4 2025 vs Q3 2023
| 指标 | | |
|---|---|---|
| 营收 | $62.1M | $4.3M |
| 净利润 | $-44.1M | — |
| 毛利率 | 52.9% | 44.9% |
| 营业利润率 | -9.0% | -396.2% |
| 净利率 | -70.9% | — |
| 营收同比 | 8.1% | — |
| 净利润同比 | -557.1% | — |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTKBPRE
| Q4 25 | $62.1M | — | ||
| Q3 25 | $52.3M | — | ||
| Q2 25 | $45.6M | — | ||
| Q1 25 | $41.5M | — | ||
| Q4 24 | $57.5M | — | ||
| Q3 24 | $51.5M | — | ||
| Q2 24 | $46.6M | — | ||
| Q1 24 | $44.9M | — |
净利润CTKBPRE
| Q4 25 | $-44.1M | — | ||
| Q3 25 | $-5.5M | — | ||
| Q2 25 | $-5.6M | — | ||
| Q1 25 | $-11.4M | — | ||
| Q4 24 | $9.6M | — | ||
| Q3 24 | $941.0K | — | ||
| Q2 24 | $-10.4M | — | ||
| Q1 24 | $-6.2M | — |
毛利率CTKBPRE
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 54.6% | — | ||
| Q1 24 | 51.3% | — |
营业利润率CTKBPRE
| Q4 25 | -9.0% | — | ||
| Q3 25 | -17.6% | — | ||
| Q2 25 | -23.3% | — | ||
| Q1 25 | -36.1% | — | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | -8.2% | — | ||
| Q2 24 | -18.3% | — | ||
| Q1 24 | -23.9% | — |
净利率CTKBPRE
| Q4 25 | -70.9% | — | ||
| Q3 25 | -10.5% | — | ||
| Q2 25 | -12.2% | — | ||
| Q1 25 | -27.5% | — | ||
| Q4 24 | 16.8% | — | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | -22.4% | — | ||
| Q1 24 | -13.8% | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $90.9M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $341.7M | — |
| 总资产 | $461.5M | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTKBPRE
| Q4 25 | $90.9M | — | ||
| Q3 25 | $93.3M | — | ||
| Q2 25 | $75.5M | — | ||
| Q1 25 | $95.3M | — | ||
| Q4 24 | $98.7M | — | ||
| Q3 24 | $162.3M | — | ||
| Q2 24 | $177.9M | — | ||
| Q1 24 | $168.8M | — |
股东权益CTKBPRE
| Q4 25 | $341.7M | — | ||
| Q3 25 | $378.6M | — | ||
| Q2 25 | $377.6M | — | ||
| Q1 25 | $379.6M | — | ||
| Q4 24 | $395.7M | — | ||
| Q3 24 | $385.5M | — | ||
| Q2 24 | $389.1M | — | ||
| Q1 24 | $392.6M | — |
总资产CTKBPRE
| Q4 25 | $461.5M | — | ||
| Q3 25 | $494.9M | — | ||
| Q2 25 | $493.3M | — | ||
| Q1 25 | $482.6M | — | ||
| Q4 24 | $499.5M | — | ||
| Q3 24 | $491.2M | — | ||
| Q2 24 | $483.7M | — | ||
| Q1 24 | $492.1M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-771.0K | — |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | — |
| 自由现金流率自由现金流/营收 | -2.9% | — |
| 资本支出强度资本支出/营收 | 1.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-8.8M | — |
8季度趋势，按日历期对齐
经营现金流CTKBPRE
| Q4 25 | $-771.0K | — | ||
| Q3 25 | $-3.9M | — | ||
| Q2 25 | $108.0K | — | ||
| Q1 25 | $-125.0K | — | ||
| Q4 24 | $2.0M | — | ||
| Q3 24 | $13.2M | — | ||
| Q2 24 | $6.2M | — | ||
| Q1 24 | $4.0M | — |
自由现金流CTKBPRE
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $-4.6M | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-974.0K | — | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $12.2M | — | ||
| Q2 24 | $5.2M | — | ||
| Q1 24 | $3.4M | — |
自由现金流率CTKBPRE
| Q4 25 | -2.9% | — | ||
| Q3 25 | -8.7% | — | ||
| Q2 25 | -3.2% | — | ||
| Q1 25 | -2.3% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 23.7% | — | ||
| Q2 24 | 11.0% | — | ||
| Q1 24 | 7.6% | — |
资本支出强度CTKBPRE
| Q4 25 | 1.6% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 2.3% | — | ||
| Q1 24 | 1.3% | — |
现金转化率CTKBPRE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 14.05× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
PRE
暂无分部数据
